<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72266">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02164929</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00047810</org_study_id>
    <nct_id>NCT02164929</nct_id>
  </id_info>
  <brief_title>Comparison Study of Transversus Abdominal Plane, Paravertebral and Epidural Blocks in Laparoscopic Colectomy</brief_title>
  <official_title>A Prospective, Randomized, Single-Blind Study to Evaluate the Efficacy of Transversus Abdominis Plane Versus Paravertebral Regional Blockade in Patients Undergoing Laparoscopic Colectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effectiveness of transversus abdominal plane
      (TAP) block, thoracic epidural or paravertebral block (PVB) for controlling postoperative
      pain when compared with opioid you self-administer in your vein using a PCA device. The
      primary outcome will be postoperative opioid consumption within 24 hours after surgery. A
      total of 120 subjects will be randomized in a 1:1:1:1 ratio to receive a TAP block, PVB, TEA
      or no block (PCA alone).Patients in all groups will be cared for using an established
      enhanced recovery after surgery (ERAS) pathway incorporating a multimodal analgesic regimen
      using IV acetaminophen and postoperative PCA fentanyl.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor recruitment
  </why_stopped>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative opioid consumption</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>If opioid other than fentanyl is used, the dose will be converted to morphine equivalent.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain scores</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an estimated 1 week</time_frame>
    <description>Pain scores at rest and with activity using a verbal rating scales (VRS) of 0-10, where &quot;0&quot; represents no pain and &quot;10&quot; represents worst pain ever, at 30, 60, 90, 120 min and every 6 hours for 24 hours and every 12 hours for 48 hours and once a day thereafter until discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of recovery</measure>
    <time_frame>72 hours</time_frame>
    <description>Quality of Recovery 15 (QoR-15) score once a day for 72 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an estimated 1 week</time_frame>
    <description>Complications using a Modified Postoperative Morbidity Survey (MPMS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First bowel movement</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an estimated 1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid related side effects</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an estimated 1 week</time_frame>
    <description>Occurrence and duration of opioid related adverse events including postoperative nausea and vomiting (PONV); pruritus, urinary retention, confusion, sedation and respiratory depression at the above time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First ingestion of solid food</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an estimated 1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epidural-related side effects</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an estimated 1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to eligibility for hospital discharge</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an estimated 1 week</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Laparoscopic Colorectal Resection</condition>
  <arm_group>
    <arm_group_label>Paravertebral block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bilateral PVB will be placed between T7-T10 interspaces preoperatively. Patients will be in a sitting position which allows easy identification of landmarks, and the patients are often more comfortable. Ultrasound will be used to identify the paravertebral space. At the appropriate dermatome under aseptic precautions, the needle (22-gauge, 8-10-cm short beveled spinal needle) will inserted 2.5-3 cm lateral to the most cephalad aspect of the spinous process and advanced perpendicular to the skin in all planes to contact the transverse process 3 of the vertebra below at a variable depth (2-4 cm). A 10 mL ropivacaine 0.25% will be injected at both T7 and T9 levels on each side (40 mL in total).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAP block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bilateral posterior and subcostal TAP blocks guided by ultrasound will be performed in the preoperative holding area. A total of 80 mL ropivacaine 0.25% (4 injections, 20 mL per injection) will be injected evenly upon identification of the appropriate planes. In the event the placement of block is uncomfortable for the patients, it will be performed after induction of anesthesia. This approach is currently practiced in the OR. Extent and degree of anesthetic blockage will be measured using a 5-point sensation scale following the procedure at 4 areas on the anterior abdominal wall (above and below the umbilicus bilaterally).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epidural</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>An epidural catheter will be inserted between T8-10 in the preoperative holding area, and a test dose of 1.5% lidocaine with 1:200,000 epinephrine will be given. Extent and degree of anesthetic blockage will be measured using a 5-point sensation following the procedure and postoperatively at 4 areas on the anterior abdominal wall (above and below the umbilicus bilaterally).
A bolus does of epidural hydromorphone (400-800 mcg) will be given preoperatively. An infusion of bupivacaine 0.25% at 4-6 ml/hour will be commenced before incision, and if tolerated, continued throughout surgery. Adjustments that may be required secondary to specific patient hemodynamic status will be left to the discretion of the individual anesthesiologist and guided by the specific patient requirements.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No block (PCA alone)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Premedication with midazolam up to 2 mg. General anesthesia is induced with propofol 1-2.5 mg/kg. Dexamethasone 4 mg IV will be administered after induction of anesthesia. Anesthesia will be maintained with sevoflurane to keep a bispectral index of between 40-60. Neuromuscular blocking drug and reversal agent of choice may be used. Local infiltration with 10 mL of plain ropivacaine 0.25% will be administered at the surgical incision site at the end of surgery. Acetaminophen 1g IV will be administered following induction of anesthesia will be administered at the end of the procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TAP block</intervention_name>
    <arm_group_label>TAP block</arm_group_label>
    <other_name>Transversus abdominus plane block</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Epidural</intervention_name>
    <arm_group_label>Epidural</arm_group_label>
    <other_name>Thoracic Epidural Anesthesia (TEA)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Paravertebral block</intervention_name>
    <arm_group_label>Paravertebral block</arm_group_label>
    <other_name>PVB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen 1g IV</intervention_name>
    <arm_group_label>Paravertebral block</arm_group_label>
    <arm_group_label>TAP block</arm_group_label>
    <arm_group_label>Epidural</arm_group_label>
    <arm_group_label>No block (PCA alone)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone 4mg</intervention_name>
    <arm_group_label>Paravertebral block</arm_group_label>
    <arm_group_label>TAP block</arm_group_label>
    <arm_group_label>Epidural</arm_group_label>
    <arm_group_label>No block (PCA alone)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam up to 2mg</intervention_name>
    <arm_group_label>Paravertebral block</arm_group_label>
    <arm_group_label>TAP block</arm_group_label>
    <arm_group_label>Epidural</arm_group_label>
    <arm_group_label>No block (PCA alone)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol 1-2.5 mg/kg</intervention_name>
    <arm_group_label>Paravertebral block</arm_group_label>
    <arm_group_label>TAP block</arm_group_label>
    <arm_group_label>Epidural</arm_group_label>
    <arm_group_label>No block (PCA alone)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane to keep a bispectral index of between 40-60</intervention_name>
    <arm_group_label>Paravertebral block</arm_group_label>
    <arm_group_label>TAP block</arm_group_label>
    <arm_group_label>Epidural</arm_group_label>
    <arm_group_label>No block (PCA alone)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Local infiltration with 10 mL of plain ropivacaine 0.25%</intervention_name>
    <arm_group_label>Paravertebral block</arm_group_label>
    <arm_group_label>TAP block</arm_group_label>
    <arm_group_label>Epidural</arm_group_label>
    <arm_group_label>No block (PCA alone)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>1.5% lidocaine</description>
    <arm_group_label>Epidural</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epinephrine</intervention_name>
    <description>1:200,000 epinephrine</description>
    <arm_group_label>Epidural</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydromorphone</intervention_name>
    <description>400-800 mcg Hydromorphone will be given preoperatively</description>
    <arm_group_label>Epidural</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Male or female, â‰¥ 18 years of age

          -  Patients scheduled to undergo laparoscopic colectomy without stoma under general
             anesthesia

          -  American Society of Anesthesiology (ASA) Physical Class 1-3.

        Exclusion Criteria:

          -  Open colectomy

          -  Perineal resection

          -  Stoma formation

          -  Patients with a contraindication to TEA or regional anesthesia.

          -  Pregnancy, nursing, or planning to become pregnant during the study or within one
             month.

          -  Long-acting opioid medication within 3 days.

          -  Any opioid medication within 24 hours.

          -  Body weight less than 50 kilograms (~110 pounds)

          -  Uncontrolled anxiety, schizophrenia, or other psychiatric disorder

          -  Current or historical evidence of any clinically significant disease or condition
             that, in the opinion of the Investigator, may increase the risk of surgery or
             complicate the subject's postoperative course.

          -  Administration of an investigational drug within 30 days or 5 elimination half-lives
             of such investigational drug, whichever is longer, prior to study drug
             administration, or planned administration of another investigational product or
             procedure during the subject's participation in this study.

          -  Suspected, or known addiction to or abuse of illicit drug(s), prescription
             medicine(s), or alcohol within the past 2 years.

          -  Significant medical conditions or laboratory results that, in the opinion of the
             Investigator, indicate an increased vulnerability to study drugs and procedures, and
             expose the subject to an unreasonable risk as a result of participating in this
             clinical trial, such as: debilitating diseases, acute illnesses, hypotension, partial
             or complete conduction block, impaired cardiac function, untreated hypertension,
             advanced arteriosclerotic heart disease, cerebral vascular insufficiency,
             pre-existing abnormal neurological or neuromuscular disease (e.g., epilepsy,
             myasthenia gravis), advanced liver disease, severe renal impairment, advanced
             diabetes, comorbid conditions associated with an immunocompromised status, such as
             blood dyscrasias, HIV/AIDS, or recent chemotherapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>February 1, 2017</lastchanged_date>
  <firstreceived_date>June 11, 2014</firstreceived_date>
  <firstreceived_results_disposition_date>November 22, 2016</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TAP block</keyword>
  <keyword>Paravertebral block</keyword>
  <keyword>Epidural</keyword>
  <keyword>Laparoscopic colectomy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Hydromorphone</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
